Program
afabicin
Also written as “Debio 1450”, “Afabicin Oral” and “Afabicin IV”.
Its studies are mostly in Bacterial Infections · Renal Insufficiency, led by Debiopharm.
Furthest: phase 2, since Apr 22, 20157 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Debiopharm | 71 open or running | phase 2since Apr 22, 2015 | Jun 10, 2014 | Dec 2027phase 1 · NCT07758608 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 10, 2014First study: phase 1 study in Bacterial InfectionsFirst studyNCT02162199 · 48 enrolled · United States
- Aug 8, 2014Phase 1 study in Bacterial InfectionsNCT02214433 · 70 enrolled · United States
- Apr 22, 2015Phase 2 study in Bacterial InfectionsNCT02426918 · 330 enrolled · United States
- Mar 29, 2016Phase 1 study in Bone Diseases, InfectiousNCT02726438 · 17 enrolled · United States
- Jul 4, 2017Phase 1 study in Healthy ParticipantsNCT03209648 · 20 enrolled · United Kingdom
- Oct 26, 2018Phase 2 study in Bone or Joint InfectionNCT03723551 · 67 enrolled · Georgia, South Africa, Ukraine
- Aug 6, 2026Phase 1 study in Renal InsufficiencyNCT07758608 · 60 planned · Germany
Ahead
- Dec 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07758608
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07758608Renal Insufficiency · Germany | 1 | Recruiting | Dec 2027 | 60 |
| NCT03723551Bone or Joint Infection · Georgia, South Africa, Ukraine | 2 | Terminated | Apr 23, 2025 | 67 |
| NCT03209648Healthy Participants · United Kingdom | 1 | Completed | Aug 23, 2017 | 20 |
| NCT02726438Bone Diseases, Infectious · United States | 1 | Completed | Jun 2017 | 17 |
| NCT02426918Bacterial Infections · United States | 2 | Completed | Aug 2016 | 330 |
| NCT02214433Bacterial Infections · United States | 1 | Completed | Feb 2015 | 70 |
| NCT02162199Bacterial Infections · United States | 1 | Completed | Oct 2014 | 48 |
How it is read
Names in the registry
- “Debio 1450”, 3 entries
- “Afabicin Oral”, 1 entry
- “Afabicin IV”, 1 entry
- “Afabicin”, 1 entry
- “Debio 1450 IV”, 1 entry
Conditions, from the studies’ own filings
- Bacterial Infections, 3 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.